Publisher
Springer Science and Business Media LLC
Subject
Pulmonary and Respiratory Medicine
Reference6 articles.
1. Dicpinigaitis PV (2021) Coming soon: the first-ever drug(s) for refractory chronic cough. Lung 199(2):83–84
2. Morice AH, Birring SS, Smith JA, McGarvey LP, Schelfhout J, Martin Nguyen A, Xu ZJ, Wu WC, Muccino DR, Sher MR (2021) Characterization of patients with refractory or unexplained chronic cough participating in a phase 2 clinical trial of the P2X3-receptor antagonist gefapixant. Lung 199(2):121–129
3. Park J-s, Burton L, Van der Wall H, Falk GL (2021) Modified reflux scintigraphy detects pulmonary microaspiration in severe gastro-esophageal and laryngopharyngeal reflux disease. Lung 199(2):139–145
4. Morice AH, Faruqi S, Wright CE, Thompson R, Bland JM (2011) Cough hypersensitivity syndrome: a distinct clinical entity. Lung 189(1):73–79
5. McGarvey L, Birring S, Morice A, Dicpinigaitis P, Pavord I, Schelfhout J, Martin Nguyen A, Li Q, Tzontcheva A, Iskold B, Green S, La Rosa C, Muccino D, Smith J (2020) Late breaking abstract—two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (COUGH-1 and COUGH-2). Eur Respir J 56(suppl 64):3800
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献